Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Coronavirus: invasive/novel

Generalities
Agent Coronaviruses belong to a large family of viruses that can cause diseases ranging from the common cold to Severe Acute Respiratory Syndrome (SARS).
1) Classical coronavirus: viruses that can infect humans and animals.
- Human coronavirus (HCoV): causing mild illness (229E, OC43, NL63, and HKU1...)
- Animal coronavirus: may infect pigs, domestic and wild birds, bats, rodents, dogs, cats and cattle. They cause acute and chronic diseases in animals such as respiratory and gastro-enteric diseases, neurologic diseases, and liver disease.
2) Novel coronavirus:
- Severe Acute Respiratory Syndrome (SARS-CoV) who caused a large outbreak in 2002-2003.
- Middle East respiratory syndrome–Novel Coronavirus (MERS-CoV): first identified in 2012
- Novel Coronavirus 2019 (COVID-19)
Incubation period - HCoV: 2-4 days
- SARS-CoV: 2-10 days (mean; 5 days)
- MERS-CoV: 2-14 days
- COVID-19: 4-7 days (up to 14 days)
Period of transmissibility - HCoV: during the active disease
- SARS-CoV: from onset to 21 days
- MERS-CoV: during illness. The duration of infectivity after resolution of symptoms is unknown.
- COVID-19: usually during illness
Reservoir - HCoV: Humans
- SARS-CoV: cave-dwelling bats (genus Rhinolophus), Himalayan masked palm civet (Paguma larvata), other wildlife animals
- MERS-CoV: may be camels and bats
Modes of transmission - HCoV: person-to-person transmission via repiratory droplets, aerosls, fecal oral route, fomites
- SARS-CoV: 1) Animal-to-person; 2) Person-to-person: while caring for, or living with a patient; via respiratory secretions, via body fluids; or airborne (aerosolized sewage, mechanical ventilation...)
- MERS-CoV: 1) Limited person-to-person transmission: close contact, when providing unprotected care to a patient; 2) Suspected animal-to-person transmission via droplet contact, fomite transmission, food-borne, airbone
- COVID-19: 1) Person-to-person: droplets (directly or indirectly), aerosol generating medical procedures, 2) Animal-to-peron
Clinical presentation - HCoV: usually self-limited illness as upper respiratory infection, otitis media, gastroenteritis. Complications: pneumonia, encephalitis, peritonitis...
- SARS-CoV: pneumonia, acute respiratory distress syndrome (ARDS). Global case fatality in 2003: 10%.
- MERS-CoV: usually, acute lower respiratory infection with or without gastrointestinal symptoms. It may be asymptomatic. The illness may be severe in people with chronic medical conditions. It may evolve to respiratory failure, organ failure (as renal failure), septic shock... Global case fatality: 27%.
- COVID-19: usually acute respiratory infection
Resources
Case definition - MOPH circular no. 35 (2012): SARS-CoV
- MOPH circular no. 37 (2014): MERS-CoV
- MOPH circular no. 42 (2020): COVID-19
Forms - General reporting form
- Novel Coronavirus reporting form
- Laboratory request form
- Patient transfert request form
- SARS-CoV investigation form
- MERS-CoV investigation form
Data - SARS-CoV: No SARS-CoV was detected in Lebanon in 2003
- MERS-CoV: 2 cases detected and confirmed in 2014 and 2017
- COVID-19: Daily report on COVID-19
Other Resources - Specimen collection for COVID-19
- Questions and Answers
- Presentation: coronavirus, A, E
- Presentation: resources, A, E
- Presentation: questions and answers, A, E
- Presentation: case definition, A, E
- Presentation: specimen collection, A, E
- Presentation: areas with community transmission, A, E
    ...
    8
    ...
ATC Name B/G Ingredients Dosage Form Price
N06BA09 PMS-ATOMOXETINE G Atomoxetine (HCl) - 18mg 18mg Capsule 3,744,073 L.L
A07EC02 PENTASA B Mesalazine - 1g 1g Tablet, controlled release 4,945,340 L.L
A07EC02 PENTASA B Mesalazine - 1g 1g Suppository 4,153,817 L.L
A07EC02 PENTASA B Mesalazine - 1g 1g Enema 2,791,161 L.L
J01CR02 POSMOX G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Powder 616,824 L.L
N02BE01 PARACETAMOL ARROW G Paracetamol - 1g 1g Tablet 80,631 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 1mg 1mg Tablet 823,775 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 1mg/ml 1mg/ml Solution 604,729 L.L
R05CB13 PULMOZYME BioTech Dornase alfa (desoxyribonuclease) - 2.5mg/2.5ml 2.5mg/2.5ml Inhalation solution 54,658,804 L.L
R05CB13 PULMOZYME BioTech Dornase alfa (desoxyribonuclease) - 2.5mg/2.5ml 2.5mg/2.5ml Inhalation solution L.L
B05AA01 PLASBUMIN-20 ALBUMIN (HUMAN) BioHuman Albumin human - 20% 20% Injectable solution 3,641,813 L.L
B01AB05 PARINOX 20 BioTech Enoxaparin sodium - 2000IU (20mg)/0.2ml 2000IU (20mg)/0.2ml Injectable solution 188,138 L.L
N05CM18 PRECEDEX (DEXMEDETOMIDINE) B Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable solution 19,441,512 L.L
N05CM18 PROXIDA G Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable concentrate for solution 1,771,184 L.L
G03DA04 PROGEST 200 G Progesterone micronised - 200mg 200mg Capsule, soft gelatin 411,216 L.L
V03AB35 PLIBADEX G Sugammadex - 200mg/2ml 200mg/2ml Injectable solution 47,914,365 L.L
A02BC02 PANTO TAD G Pantoprazole (sodium) - 20mg 20mg Tablet, gastroresistant 294,302 L.L
A02BC02 PANTOMAX G Pantoprazole (sodium sesquihydrate) - 20mg 20mg Tablet, enteric coated 440,780 L.L
A02BC02 PANTOMAX G Pantoprazole (sodium sesquihydrate) - 20mg 20mg Tablet, enteric coated 837,214 L.L
A02BC04 PARIET B Rabeprazole (sodium) - 20mg 20mg Tablet, gastroresistant 779,429 L.L
A02BC04 PRASOLAN G Rabeprazole sodium - 20mg 20mg Tablet, enteric coated 230,373 L.L
A02BC04 PULOROS 28 G Rabeprazole sodium - 20mg 20mg Tablet, gastroresistant 706,861 L.L
C10AA07 PMS-ROSUVASTATIN G Rosuvastatin (calcium) - 20mg 20mg Tablet 564,414 L.L
A02BC05 PRIMAZOL 20 G Esomeprazole (magnesium dihydrate) - 20mg 20mg Capsule, gastro-resistant 511,940 L.L
N06AB03 PMS-FLUOXETINE G Fluoxetine (HCl) - 20mg 20mg Capsule 592,635 L.L
N06AB03 PROXETIN G Fluoxetine (HCl) - 20mg 20mg Capsule 374,996 L.L
N06AB05 PARLOTIN G Paroxetine (HCl) - 20mg 20mg Tablet 894,999 L.L
    ...
    8
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026